Meeting public demand for an urgently needed effective medication quickly and safely during a pandemic involves difficult tradeoffs.
In the midst of the COVID-19 pandemic, patients with lung cancer face an increased risk of disease progression, reduced survival, and worse quality of life associated with delayed treatment.
The Advisory Committee on Immunization Practices encourages all Americans to receive the flu vaccine between September and October.
PAH associated with CHD is linked to significant reductions in survival and quality of life, especially for patients progressing to Eisenmenger syndrome.
Obstructive sleep apnea may represent another important variable contributing to increased risk related to COVID-19.
The American College of Rheumatology developed guidance for the management of pediatric patients with multisystem inflammatory syndrome associated with COVID-19.
Individuals with pulmonary fibrosis could develop more serious complications if infected with COVID-19, and those awaiting organ transplantation and other surgical interventions may face delays because of the pandemic.
Putting information in the cloud can be a good move for a physician’s practice — but only if done well.
COVID-19 has brought unprecedented stress to society at large and perhaps most of all to frontline healthcare teams in a variety of settings.
Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.